Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8527615 | 1.00 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL8527609 | 1.00 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| Water SCHEMBL29655402 | 0.99 | MME (0.43) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL31453800 | 0.94 | OPRM1 (0.40) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30974040 | 0.92 | OPRM1 (0.42) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30254475 | 0.92 | OPRM1 (0.39) | MMEECE1CD274PDCD1LG2OPRM1 | |
| SCHEMBL30997434 | 0.91 | MME (0.38) | MMECD274PDCD1LG2OPRM1OPRD1 | |
| SCHEMBL8437182 | 0.91 | MME (0.37) | MMEECE1CA2CA1 | |
| SCHEMBL8437180 | 0.91 | MME (0.37) | MMEECE1CA2CA1 | |
| SCHEMBL29794242 | 0.91 | MME (0.36) | MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12269856-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11807674-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4091624-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269856-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | MME 345/4885ECE1 556/4885CD274 4217/4885 |
| US-11807674-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | MME 345/4885ECE1 556/4885CD274 4217/4885 |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | MME 345/4885ECE1 556/4885CD274 4217/4885 |
| US-20240174726-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | MME 345/4885ECE1 556/4885CD274 4217/4885 |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | MME 345/4885ECE1 556/4885CD274 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.